IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| Applicants: | P. Bornstein et al. | Attorney Docket No.: | UWOTL117618 |
| Application No.: | 09/919,770 | Group Art Unit: | 1635 |
| Filed: | July 31, 2001 | Examiner: | Terra C. Gibb |

Title: METHODS AND DEVICES TO MODULATE THE WOUND RESPONSE

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

#8/K.T. 11/9 ELECT. A

Seattle, Washington 98101

October 29, 2002

TO THE COMMISSIONER FOR PATENTS:

In the Claims:

Please amend Claim 15 as follows, and cancel Claims 8-9 and 19-27.

1. A method of modulating the amount or biological activity of thrombospondin 2 or osteopontin in an animal, said method comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to modulate the amount or biological activity of thrombospondin 2 or osteopontin in the animal.

N.E.

2. The method of Claim 1 wherein an antagonist of thrombospondin 2 is introduced into the animal.

3. The method of Claim 2 wherein the amount or biological activity of thrombospondin 2 is decreased by said antagonist of thrombospondin 2.

4. The method of Claim 2 wherein the thrombospondin 2 antagonist is selected from the group consisting of an antisense thrombospondin 2 nucleic acid molecule, an anti-thrombospondin 2 antibody, a thrombospondin 2 blocking peptide and a thrombospondin 2 ribozyme.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

5. The method of Claim 4 wherein an antisense thrombospondin 2 nucleic acid molecule is introduced into the animal.

6. The method of Claim 5 wherein the antisense thrombospondin 2 nucleic acid molecule is at least ninety percent identical to the complement of a thrombospondin 2 cDNA consisting of the nucleic acid sequence set forth in SEQ ID NO. 3.

7. The method of Claim 5 wherein the antisense thrombospondin 2 nucleic acid molecule hybridizes under stringent conditions to a thrombospondin 2 cDNA molecule consisting of the nucleic acid sequence set forth in SEQ ID NO. 3.

10. The method of Claim 4 wherein a thrombospondin 2 ribozyme is introduced into the animal.

N.E.

11. The method of Claim 1 wherein osteopontin is introduced into the animal.

12. The method of Claim 1 wherein the molecule is introduced into the animal by a method selected from the group consisting of injection, as a component of a lipid complex, as a component of an implanted porous matrix, and by immobilization onto an implanted surface.

13. The method of Claim 5 wherein an antisense thrombospondin 2 nucleic acid molecule is incorporated within a delivery device which is introduced into the animal.

14. The method of Claim 13 wherein the delivery device comprises a porous matrix wherein the thrombospondin 2 antisense nucleic acid molecule is disposed.

15. (Amended) The method of Claim 1 wherein the animal is exhibiting a wound response, and the amount of the introduced molecule is effective to improve the wound response.

16. The method of Claim 15 wherein the molecule is an antisense thrombospondin 2 nucleic acid molecule.

N.E.

17. The method of Claim 1 wherein osteopontin and an antagonist of thrombospondin 2 are introduced into the animal.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

N.E. 18. The method of Claim 17 wherein the antagonist to thrombospondin 2 is an antisense thrombospondin 2 nucleic acid molecule.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100